Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

[1]  I. Oda,et al.  Epidemiological Trends and Future Perspectives of Gastric Cancer in Eastern Asia , 2021, Digestion.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2018 (5th edition) , 2020, Gastric Cancer.

[4]  M. Saruta,et al.  Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis , 2019, Investigational New Drugs.

[5]  S. Carmichael,et al.  Variants , 2018, The Works of Aphra Behn.

[6]  J. Vauthey,et al.  The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia , 2018, Journal of the National Cancer Institute.

[7]  K. Chìn,et al.  Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel , 2018, Oncotarget.

[8]  N. Sugimoto,et al.  Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer , 2016, Gastric Cancer.

[9]  Chikuma Hamada,et al.  Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer , 2016, Gastric Cancer.

[10]  O. Matsui,et al.  Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome , 2015, Abdominal Imaging.

[11]  Thomas J. Smith,et al.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K Nishikawa,et al.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[14]  E. Oki,et al.  Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Shibasaki,et al.  Hepatic sinusoidal obstruction associated with S-1 plus cisplatin chemotherapy for highly advanced gastric cancer with paraaortic lymph node metastases: report of a case , 2012, Clinical Journal of Gastroenterology.

[17]  J. Vauthey,et al.  Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[19]  P. Bachellier,et al.  Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy , 2008, Annals of surgery.

[20]  J. Schellens,et al.  Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. , 2007, British journal of clinical pharmacology.

[21]  H. McLeod,et al.  Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics , 2007, Clinical pharmacology and therapeutics.

[22]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[23]  S. Curley,et al.  Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Hawkins,et al.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.

[25]  A. Sparreboom,et al.  Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.

[26]  T. Masaoka.  Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  G. Rosner,et al.  Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Burstein,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[30]  Thomas J. Smith,et al.  Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Kearney,et al.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.

[32]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..